The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

28 May 2019 10:20

RNS Number : 3304A
GoldmanSachs International
28 May 2019
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

(GS) GOLDMAN SACHS INTERNATIONAL

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

TARSUS GROUP PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

TIGER ACQUISITIONS UK LIMITED (A WHOLLY-OWNED INDIRECT SUBSIDIARY OF FUNDS ADVISED BY CHARTERHOUSE CAPITAL PARTNERS LLP)

(d) Date dealing undertaken:

24 May 2019

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

5p ordinary

Purchases

63,069

4.2900 GBP

4.2600 GBP

5p ordinary

Sales

63,069

4.2900 GBP

4.2621 GBP

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising / exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

28 May 2019

Contact name:

Kashif Rafiq and Papa Lette

Telephone number:

+44(20) 7051 0547 / +44(20) 7774 7442

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERGCGDUIBDBGCI
Date   Source Headline
12th Jan 20187:00 amRNSTrading Update & launch of next phase of strategy
29th Dec 201710:03 amRNSTotal Voting Rights
13th Dec 20173:22 pmRNSScrip Dividend Circular (the "Circular")
5th Dec 201711:45 amRNSHolding(s) in Company
30th Nov 201710:33 amRNSTotal Voting Rights and Capital
21st Nov 20177:00 amRNSCapital Markets Seminar and Trading Update
14th Nov 20177:00 amRNSSite visit to Dubai Airshow
9th Nov 201710:41 amRNSBlock Listing Six Monthly Return
2nd Nov 20177:00 amRNSChange of Advisers
12th Oct 20177:00 amRNSTrading Statement
26th Sep 20177:00 amRNSAnalyst and Investor Site Visit
22nd Sep 20173:55 pmRNSHolding(s) in Company
12th Sep 20177:00 amRNSExpansion of Mexican Joint Venture
6th Sep 201711:38 amRNSBlock Listing Six Monthly Return
31st Aug 20179:31 amRNSTotal Voting Rights
29th Aug 20173:31 pmRNSDirector/PDMR Shareholding
16th Aug 20174:07 pmRNSHalf-year Report
2nd Aug 20171:38 pmRNSDirector/PDMR Shareholding
31st Jul 20172:42 pmRNSTotal Voting Rights
27th Jul 20175:05 pmRNSDirector/PDMR Shareholding
26th Jul 20177:00 amRNSHalf-year Report
11th Jul 201712:42 pmRNSApplication for Admission
30th Jun 20174:09 pmRNSTotal Voting Rights
21st Jun 201712:13 pmRNSResult of AGM
5th Jun 201711:24 amRNSScrip Dividend Circular
31st May 201710:09 amRNSTotal Voting Rights
19th May 20171:42 pmRNSNotice of AGM
18th May 201712:05 pmRNSHolding(s) in Company
17th May 20177:00 amRNSTrading Update
9th May 20172:45 pmRNSBlock Listing Six Monthly Return
28th Apr 201711:05 amRNSTotal Voting Rights
4th Apr 20175:17 pmRNSHolding(s) in Company
4th Apr 20175:16 pmRNSDirector/PDMR Shareholding
31st Mar 201710:37 amRNSTotal Voting Rights
30th Mar 20176:10 pmRNSDirector/PDMR Shareholding
17th Mar 20172:01 pmRNS2016 Annual Report
16th Mar 20172:29 pmRNSDirector/PDMR Shareholding
15th Mar 20178:41 amRNSHolding(s) in Company
6th Mar 20175:45 pmRNSDirector/PDMR Shareholding
6th Mar 20175:44 pmRNSDirector/PDMR Shareholding
1st Mar 20174:04 pmRNSApplication for Block Listing
1st Mar 20177:00 amRNSFinal Results
8th Feb 201712:19 pmRNSDirector Declaration
1st Feb 201712:02 pmRNSTotal Voting Rights
25th Jan 20177:00 amRNSCompletion of acquisition
17th Jan 201711:14 amRNSApplication for Admission
10th Jan 20177:00 amRNSYear-end Trading Update
30th Dec 20169:03 amRNSTotal Voting Rights
22nd Dec 20167:12 amRNSAcquisition of Hometex
14th Dec 20163:26 pmRNSScript Dividend Circular

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.